Horizon Therapeutics Public (NASDAQ:HZNP) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a report issued on Sunday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Separately, TheStreet downgraded shares of Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a research note on Monday, May 8th. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Horizon Therapeutics Public currently has a consensus rating of “Hold” and a consensus target price of $111.42.

Horizon Therapeutics Public Price Performance

Horizon Therapeutics Public stock opened at $100.75 on Friday. The stock has a market cap of $23.03 billion, a price-to-earnings ratio of 63.37, a PEG ratio of 3.02 and a beta of 1.13. The company has a quick ratio of 3.89, a current ratio of 4.07 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $109.25 and a 200 day simple moving average of $105.10. Horizon Therapeutics Public has a 52 week low of $57.84 and a 52 week high of $113.83.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 EPS for the quarter, missing the consensus estimate of $1.17 by ($0.34). The business had revenue of $832.10 million for the quarter, compared to analysts’ expectations of $897.06 million. Horizon Therapeutics Public had a return on equity of 20.31% and a net margin of 10.40%. The firm’s revenue for the quarter was down 6.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 EPS. On average, research analysts forecast that Horizon Therapeutics Public will post 4.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Horizon Therapeutics Public

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Horizon Therapeutics Public by 1.7% during the third quarter. Vanguard Group Inc. now owns 21,276,662 shares of the biopharmaceutical company’s stock valued at $1,316,812,000 after purchasing an additional 354,287 shares during the period. BlackRock Inc. increased its position in shares of Horizon Therapeutics Public by 7.0% in the third quarter. BlackRock Inc. now owns 15,619,023 shares of the biopharmaceutical company’s stock valued at $966,660,000 after acquiring an additional 1,020,576 shares during the period. Avoro Capital Advisors LLC raised its stake in shares of Horizon Therapeutics Public by 36.6% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,000,000 shares of the biopharmaceutical company’s stock valued at $796,600,000 after acquiring an additional 1,875,000 shares during the last quarter. State Street Corp boosted its holdings in shares of Horizon Therapeutics Public by 3.4% during the third quarter. State Street Corp now owns 5,732,387 shares of the biopharmaceutical company’s stock worth $354,777,000 after purchasing an additional 188,413 shares during the period. Finally, Farallon Capital Management LLC grew its stake in shares of Horizon Therapeutics Public by 46.7% in the first quarter. Farallon Capital Management LLC now owns 5,419,823 shares of the biopharmaceutical company’s stock worth $591,519,000 after purchasing an additional 1,724,900 shares during the last quarter. 91.01% of the stock is currently owned by institutional investors.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.